Across Asia Pacific, a quiet but consequential shift is underway in how pharmaceutical companies speak to the people they serve. Adeline Lim, Menarini's APAC CMO, has spent two years arguing that medicine's most persistent marketing failure is treating human beings as secondary to compounds — and building a practice that places empathy, cultural fluency, and creative courage alongside clinical evidence. Her work is a reminder that trust, not technology, remains the deepest currency in healthcare.
Pharma's future demands empathy alongside science, says Menarini APAC CMO
Science alone is no longer enough in a region as diverse as Asia Pacific.
Mark
So Lim is saying pharma marketing has been too focused on the science. But isn't that the whole point? Drugs work or they don't.
Mimi
That's true, but there's a difference between having good science and knowing how to communicate it in a way that actually reaches people. Dermatix is a scar cream. But Menarini spent five years understanding that mothers recovering from C-sections weren't just worried about scars—they were worried about their bodies, their identity, their recovery. Once you know that, you can market to the actual person, not just the condition.
Luke
But we should be careful here. The Dermatix numbers are real—brand awareness did go from 47 to 67 percent. But we don't know if that's because of the insight work or because of media spend, or distribution, or all of it together. The source doesn't isolate the variable.
Mark
Fair point. So what's actually new about what Lim is doing? Isn't understanding your customer Marketing 101?
Mimi
In consumer goods, yes. But pharma has historically marketed to doctors, not patients. The entire infrastructure—the regulations, the sales force, the messaging—was built around clinical evidence for professionals. Lim is saying that's changing because patients are now buying consumer healthcare products directly. You can't sell to them the way you sell to a cardiologist.
Luke
And that's where the China example gets interesting. The "East meets West" strategy for shingles treatment—that's not just empathy, that's recognizing a genuine gap in how Western pharma companies approach markets. But again, the Blue Book Project reached 600 hospitals and 2,000 professionals. That's significant, but we don't know the actual clinical or commercial impact. We know it generated 100 million media impressions, but impressions aren't outcomes.
Mark
So the real question is: does this philosophy actually sell more medicine?
Mimi
Dermatix became market leader. That's a commercial outcome. And the HYIMPACT study in cardiovascular disease—that's 1,765 patients across seven markets generating region-specific evidence. That's not just marketing; that's building trust through data.
Luke
Right, but HYIMPACT is a clinical study, not a marketing campaign. It's good work, but it's a different thing. The narrative conflates marketing strategy with clinical research, and they're not the same.
Mark
What about the risk-taking in a regulated industry? How real is that?
Mimi
That's the tension Lim is naming. Pharma is heavily regulated for good reason—you're talking about people's health. But that creates a culture where everyone defaults to safe, cautious messaging. She's saying you can be creative and compliant at the same time. You just have to be intentional about it.
Luke
The source doesn't give us examples of what that creative risk-taking actually looks like, though. We hear the philosophy, but not the practice. What did they try that was bold? What got rejected? We don't know.
The Pulse
- Pharmaceutical marketing has long prioritized regulatory compliance and clinical data over the lived experiences of patients and doctors, leaving a widening gap between science and human need.
- Menarini's Dermatix brand exposed this tension directly — a scar treatment that only became a market leader once the company spent five years mapping the emotional recovery journeys of real patients across nine markets.
- In China, the company's refusal to pit Western medicine against traditional Chinese medicine unlocked a partnership model — the Blue Book Project — now operating across 600 hospitals and reaching over 2,000 healthcare professionals.
- Digital channels, AI personalization, and the rise of informed healthcare consumers are accelerating pressure on pharma brands to show up meaningfully across platforms far beyond the clinic.
- Lim's framework — problem-solving over product-selling, customer stories over compound data, and creative risk-taking within regulated boundaries — is positioning Menarini as a test case for what modern pharma marketing can become.
Across Asia Pacific, a quiet but consequential shift is underway in how pharmaceutical companies speak to the people they serve. Adeline Lim, Menarini's APAC CMO, has spent two years arguing that medicine's most persistent marketing failure is treating human beings as secondary to compounds — and building a practice that places empathy, cultural fluency, and creative courage alongside clinical evidence. Her work is a reminder that trust, not technology, remains the deepest currency in healthcare.
Adeline Lim arrived at Menarini with a conviction the pharmaceutical industry has been slow to accept: that marketing a medicine is, at its core, a problem of people rather than a problem of science. Over two years as APAC CMO, she has pushed the company toward an approach that preserves clinical rigor while wrapping it in empathy, cultural understanding, and genuine creative ambition.
Her philosophy was forged across two worlds. Pharma gave her an uncompromising respect for scientific credibility. A stint in medical technology showed her something pharma often lacks — faster innovation cycles, user-centric design, and the belief that how a product feels to use matters as much as what it does. Lim has tried to hold both truths at once, building marketing that is disciplined enough for regulators and human enough for patients.
The clearest proof of concept is Dermatix, Menarini's largest consumer healthcare brand. Rather than promoting a scar treatment on clinical grounds alone, the company commissioned a five-year insight study across nine Asia Pacific markets, tracing the emotional arc of mothers recovering from Caesarean deliveries — their anxiety, their hope, their relationship with their own healing bodies. That research allowed Menarini to reposition Dermatix as a recovery partner rather than a medical product. Brand awareness climbed from 47 percent in 2020 to 67 percent in 2025, and the brand became market leader across multiple countries.
In China, Menarini found a different kind of lesson. Western pharmaceutical companies frequently overlook the complementary role traditional Chinese medicine plays alongside Western treatments. Rather than competing with that reality, Menarini built an 'East meets West' strategy for shingles treatment, collaborating with medical societies to produce the Blue Book Project — a standardized, real-world-data protocol now active in more than 600 hospitals and generating over 100 million media impressions.
Lim is careful not to let any of this obscure the foundational truth: without clinical integrity, nothing else holds. But she argues that science alone is no longer sufficient in a region as diverse and digitally connected as Asia Pacific. The real work — now and as AI and e-commerce reshape healthcare — is the creative translation of complex evidence into something that genuinely matters to the people whose lives depend on it.
Adeline Lim has spent more than two years reshaping how Menarini markets pharmaceuticals across Asia Pacific, and her conviction is straightforward: the industry has spent decades treating marketing as a problem of science and regulation when it should have been treating it as a problem of people.
When Lim took the role, she inherited an organization built on the traditional pharmaceutical playbook—clinical evidence, regulatory compliance, product messaging aimed at healthcare professionals. She has since pushed the company toward what she calls a more human approach, one that still honors scientific rigor but wraps it in empathy, creativity, and genuine understanding of what patients and doctors actually need. The shift rests on three pillars: moving from selling products to solving problems, making data tell the story of the customer rather than just the compound, and building a culture where marketers feel safe taking calculated creative risks inside one of the world's most tightly regulated industries.
Lim's own career path shaped this philosophy. She has worked in both pharmaceutical and medical technology companies, and the contrast between them proved instructive. Pharma taught her the non-negotiable importance of scientific credibility and clinical rigor. Medtech showed her something different: faster innovation cycles, user-centric thinking, and the idea that a product's experience matters as much as its efficacy. She has tried to marry both sensibilities—maintaining the discipline pharma demands while adopting the agility and creativity that medtech embraces. The result is a view of marketing not as promotion but as the design of an entire healthcare experience.
This matters because Menarini is no longer only a company that hospitals and specialists know. Its consumer healthcare and aesthetics businesses mean patients themselves are now central to the conversation. Patients today are more informed, more proactive, more likely to research their conditions and compare options. Menarini's ambition, Lim said, is to be recognized across Asia Pacific not just by doctors but by consumers as a genuine partner in their health.
The company's work with Dermatix, its largest consumer healthcare brand, illustrates what this approach can accomplish. Rather than simply marketing a scar treatment, Menarini invested in a five-year consumer insight study across nine Asia Pacific markets. The research went deeper—it traced the emotional journey of mothers recovering from Caesarean deliveries, the anxiety and hope they carried, the way they thought about their bodies healing. That understanding allowed the company to reposition Dermatix not as a medical product but as a recovery partner. Brand awareness rose from 47 percent in 2020 to 67 percent in 2025. Dermatix became the market leader across multiple countries.
In China, Menarini recognized something that Western pharmaceutical companies often miss: the complementary relationship between Western medicine and traditional Chinese medicine in treating shingles. Rather than positioning one against the other, the company developed an "East meets West" strategy that combined global clinical standards with locally trusted practices. This led to the Blue Book Project, created with medical societies to standardize treatment protocols using real-world data. The program now operates across more than 600 hospitals, reaches over 2,000 healthcare professionals, and has generated more than 100 million media impressions.
Lim is clear that none of this diminishes the role of science. "Without clinical integrity, nothing else holds," she said. In healthcare, trust is the most important currency. But science alone is no longer sufficient in a region as diverse as Asia Pacific. The work demands digital and e-commerce capabilities to reach mobile-first populations. It demands data and AI to enable personalized engagement. And it demands what Lim calls creative translation—the ability to take complex scientific information and make it meaningful, accessible, and culturally relevant to the people who need it.
As healthcare marketing moves increasingly online and influencer partnerships grow more common, Lim noted that healthcare professionals remain highly influential, particularly at the point of diagnosis. But their role has expanded beyond hospitals into pharmacies, e-commerce platforms, and patient education. The challenge is integrating these channels so they support patients holistically rather than simply broadcasting messages.
Ultimately, Lim's argument is that pharmaceutical marketing's future depends on balancing scientific discipline with cultural understanding, using creativity not to simplify the science but to make it matter more deeply to the people whose lives depend on it. As digital channels, AI, and consumer expectations continue to shift, that balance—not the technology—remains the real work.
Notable Quotes
Without clinical integrity, nothing else holds. In healthcare, trust is the most important currency.— Adeline Lim, CMO of Menarini APAC
You need the digital and eCommerce capabilities to reach increasingly mobile-first populations. You need data and AI to deliver more personalised engagement. Equally important is creative translation, the ability to take complex scientific information and turn it into something meaningful, accessible and culturally relevant.— Adeline Lim
Want the full story?
Read the original at Marketing-Interactive ↗
Health & Medicine